U.S. markets closed
  • S&P Futures

    3,973.50
    -3.25 (-0.08%)
     
  • Dow Futures

    32,079.00
    +3.00 (+0.01%)
     
  • Nasdaq Futures

    11,905.25
    -37.00 (-0.31%)
     
  • Russell 2000 Futures

    1,797.60
    +0.80 (+0.04%)
     
  • Crude Oil

    110.80
    +0.47 (+0.43%)
     
  • Gold

    1,851.90
    +5.60 (+0.30%)
     
  • Silver

    21.97
    +0.11 (+0.50%)
     
  • EUR/USD

    1.0689
    +0.0005 (+0.04%)
     
  • 10-Yr Bond

    2.7490
    -0.0110 (-0.40%)
     
  • Vix

    28.37
    -1.08 (-3.67%)
     
  • GBP/USD

    1.2587
    +0.0008 (+0.07%)
     
  • USD/JPY

    127.1930
    -0.0480 (-0.04%)
     
  • BTC-USD

    29,559.17
    -94.27 (-0.32%)
     
  • CMC Crypto 200

    656.87
    -14.13 (-2.11%)
     
  • FTSE 100

    7,522.75
    +38.40 (+0.51%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus of $5.44 million.

  • FY21 revenue is expected to be $17.5 million - $17.9 million (consensus $17.13 million), more than doubled from FY20.

  • Bionano also reported a record net increase in the installed base of 23 Saphyr systems in Q4, bringing the year-end total to 164, representing a 69% increase over the 97 installed systems reported at the end of 2020 and exceeding goal 150 systems.

  • "We ended the year with much momentum across the business and have achieved or exceeded all of the milestones we set out at the beginning of 2021," commented Erik Holmlin, President and CEO. "The integration of BioDiscovery is going well and the results from our first interim readout from our postnatal clinical trial exceeded our expectations."

  • Price Action: BNGO shares are up 1.46% at $2.78 during the market session on the last check Wednesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.